Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Synlogic, Inc.

Synlogic Reports Third Quarter 2024 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports Second Quarter 2024 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports First Quarter 2024 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Adopts Limited Duration Stockholders Rights Plan
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Provides Corporate Update and Outlook for 2024
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Contract with the Air Force Research Lab
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Reverse Stock Split
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic to Participate in Chardan’s Genetic Medicines Conference
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic to Present at the Jefferies Global Healthcare Conference
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
From Synlogic, Inc.
Via GlobeNewswire
Tickers SYBX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.